氯雷他定-倍他米松口服溶液治疗儿童重度常年性变应性鼻炎的临床疗效和安全性。
Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis.
机构信息
From the 1Instituto de Otorrinolaringologia San Bernardino, Caracas, Venezuela; and 2Policlinica Metropolitana, Caracas, Venezuela.
出版信息
World Allergy Organ J. 2009 Apr;2(4):49-53. doi: 10.1097/WOX.0b013e31819f2105.
BACKGROUND
: Allergic rhinitis is a highly prevalent condition, particularly among children, whose schoolwork and quality of life may be impaired by its symptoms.
METHODS
: In this prospective, multicenter study, children between 6 and 12 years old with a diagnosis of severe perennial allergic rhinitis received a combination of the nonsedating antihistamine loratadine and the corticosteroid betamethasone in an oral solution for 5 days.
RESULTS
: The total nasal and ocular symptom score was significantly reduced from 11.4 (±2.1) before treatment to 2.9 (±2.4) after treatment (P < 0.01). Significant reductions (P < 0.01) were also observed for sneezing, nasal pruritus, nasal congestion, rhinorrhea, postnasal drip, and ocular erythema and pruritus. No adverse events were reported, and no subject discontinued treatment.
CONCLUSIONS
: The combination of loratadine and betamethasone in an oral solution was safe and effective as initial short-term treatment for symptoms of severe perennial allergic rhinitis in school-aged children.
背景
变应性鼻炎是一种高度流行的疾病，特别是在儿童中，其症状可能会影响他们的学业和生活质量。
方法
在这项前瞻性、多中心研究中，6 至 12 岁被诊断为严重常年性过敏性鼻炎的儿童接受了非镇静抗组胺药氯雷他定和皮质类固醇倍他米松的口服溶液联合治疗，为期 5 天。
结果
总鼻和眼症状评分从治疗前的 11.4（±2.1）显著降低至治疗后的 2.9（±2.4）（P＜0.01）。打喷嚏、鼻痒、鼻塞、流涕、鼻后滴注以及眼红和眼痒也有显著改善（P＜0.01）。无不良反应报告，无受试者停止治疗。
结论
氯雷他定和倍他米松口服溶液联合治疗作为严重常年性变应性鼻炎患儿的初始短期治疗，安全有效。
Zotero 插件